MedTrace Logo

Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT

NCT04822792 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 11879

Last updated 2021-06-02

No results posted yet for this study

Summary

PRESCIENT is a multi-center, prospective observational study aimed to detect cancers early by combined assays for serum protein markers and cell-free DNA (cfDNA) methylation markers. Blood RNA markers will also be evaluated. The study will enroll approximately 11879 participants, including participants with malignancies or benign diseases, and healthy participants.

Conditions

Interventions

DEVICE

Multi-cancer early detection test

Blood collection and multi-cancer early detection test

Sponsors & Collaborators

  • Guangzhou Burning Rock Dx Co., Ltd.

    collaborator INDUSTRY

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Jie Wang, M.D., Ph.D · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2023-03-31
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04822792 on ClinicalTrials.gov